Sigachi Industries Ltd (SIGACHI) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Full-year revenue guidance for FY27 is revised down from INR 650 crores to ~INR 600 crores due to capex delays.
- The 12,000 MTPA MCC and CCS capacity expansions at Dahej are now delayed by six months, with commissioning expected in Q2 FY28.
- Management is guiding for a significant margin recovery to over 18% in H2, driven by higher utilization and an improved sales mix.
Performance Overview
- The company is focused on translating strategic priorities into measurable business outcomes, strengthening its core excipients business while diversifying into API, O&M, and food & nutrition.
- Disciplined execution, operational efficiency, and profitable growth remain key areas of emphasis across all business verticals.
- Innovation efforts continued with the launch of four new offerings under the PureCoat portfolio to address evolving customer requirements.
- The API business is progressing with portfolio expansion and strengthening regulatory readiness, while the O&M vertical remains a stable contributor.
- Major capacity expansion projects for MCC and CCS at Dahej are underway, reinforcing the company's long-term growth strategy.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.